Merck’s Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.
Ervebo, an Ebola vaccine from Merck, received marketing approval from the European Commission today (November 11), marking the first such vaccine to reach the world’s markets.
“Finding a vaccine as soon as possible against this terrible virus has been a priority for the international community ever since Ebola hit West Africa five years ago,” Vytenis Andriukaitis, the European Commission official in charge of health and food safety, says in a statement.
Source: The Scientist